|MDACC Study No:||2013-0147 (clinicaltrials.gov NCT No: NCT01856023)|
|Title:||Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy«) in Patients with Metastatic Melanoma|
|Principal Investigator:||Sapna P. Patel|
|Treatment Agent:||HDIL-2; Ipilimumab|
|Study Description:||The goal of this clinical research study is to compare if and how long 2 |
different study treatment plans with aldesleukin (also known as interleukin-2
or IL-2) and ipilimumab may be able to help control metastatic melanoma. The
safety of these treatment plans will also be studied.